Clinical Trials Logo

Clinical Trial Summary

1. Test for Helicobacter pylori. The test items include urease test, histology, bacterial culture, serology, and urea breath test. At least two positive results can be used to confirm the diagnosis. 2. To ensure that the research results are not artificially distorted, this trial is a randomized study. Random allocation (which means that the subjects will use the "random number table generated by a computer similar to the lottery" to determine the treatment group) accept one of the following schemes (1:1:1).


Clinical Trial Description

Helicobacter pylori (H.pylori) infect more than 50% of humans globally. This study were (1) to test whether the efficacies of 14-day PCAB-based high-dose dual therapy and 14-day PPI-based reverse hybrid therapy can achieve a higher eradication rate than 14-day PCAB-based triple therapy in the first-line treatment of H pylori infection, (2) to compare the eradication rates of 14-day PCAB-based and PPI-based bismuth quadruple therapies in the second-line treatment of H pylori infection, and (3) to examine the impacts of antibiotic resistance of H pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of anti-H pylori treatments. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05191888
Study type Interventional
Source Kaohsiung Medical University
Contact Deng-Chyang Wu, MD, PhD
Phone 886-7-*3121101
Email [email protected]
Status Recruiting
Phase Phase 4
Start date August 6, 2021
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT02873065 - Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori Phase 4
Completed NCT03924375 - Serum Pepsinogen After H. Pylori Eradication
Recruiting NCT04034641 - Effect of Probiotics on Helicobacter Pylori Eradication Phase 4
Recruiting NCT04850209 - The Impact of WeChat Group Patient Education on the Eradication Rate of Helicobacter Pylori N/A
Not yet recruiting NCT04558502 - Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication Phase 4